Daiwa Securities Group
AVBP icon

Daiwa Securities Group’s ArriVent BioPharma AVBP Stock Holding History

Daiwa Securities Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-111
Closed -$2K – 1461
2025
Q4 		$2K Hold
111
– – ﹤0.01% 1332
2025
Q3 		$2K Hold
111
– – ﹤0.01% 1291
2025
Q2 		$2K Hold
111
– – ﹤0.01% 1240
2025
Q1 		$2K Hold
111
– – ﹤0.01% 1205
2024
Q4 		$3K Buy
+111
New +$3.19K ﹤0.01% 1206

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Daiwa Securities Group's AVBP Position: Q1 2026 in Review

Daiwa Securities Group sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 111 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in AVBP in Q4 2024 and held it in 5 quarters. The position peaked at $3K in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Daiwa Securities Group reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 111 ArriVent BioPharma shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in ArriVent BioPharma in Q4 2024 and held it in 5 quarters.
  • Daiwa Securities Group's ArriVent BioPharma position peaked at $3K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.